Scholar Rock Holding Corporation (SRRK) Stock: Price, Forecast & Analyst Target
Scholar Rock Holding Corporation (SRRK) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $48.13 (-4.45%), as of the Nov 20, 2026 trading session; market cap $5.87B.
Educational signal · not a buy or sell recommendation · How to read this
Scholar Rock Holding Corporation · SRRK · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Scholar Rock develops treatments that target protein growth factor signaling, anchored by a late-stage candidate for spinal muscular atrophy. Because the company currently generates no commercial revenue, the investment case rests entirely on whether its clinical trial data can secure regulatory approval and transition the pipeline into a marketed product.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Scholar Rock Holding (SRRK)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, stalling growth and an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Rising.
- EPS beat 0 of the last 3 reports
- Altman Z 4.80 · Piotroski F 3
Holding back: weak fundamentals, soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $48.13 | |
| Change on the day | -4.45% | |
| 52-week range | $37.54–$61.76 | |
| Market capitalisation | $5.87B | — |
| Price / earnings (trailing) | -21.42 | |
| Shares traded on the day | 2.08M | |
| Beta (volatility vs the S&P 500) | 0.79 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Scholar Rock Holding (SRRK): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Scholar Rock Holding (SRRK), and what does it report?
Short answer · as of
Scholar Rock operates as a clinical-stage biopharmaceutical developer focused on serious diseases like spinal muscular atrophy and treatment-resistant cancers.
Research dated 2026-09-13.
Although the standard industry classification groups it with broad healthcare providers, the business functions strictly as a research engine that consumes cash to advance experimental therapies through trials.
Its income statement measures the heavy cost of scientific development against a complete lack of commercial sales, with research and development expenses constituting the bulk of its operational drain.
What do the latest results show for Scholar Rock Holding (SRRK)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 3 reports.
Research dated 2026-09-13.
The latest financial results show widening net losses as the company funds late-stage clinical evaluations for its lead spinal muscular atrophy candidate. Without product revenue to offset costs, operating deficits grow directly in proportion to the rising expenses of clinical trials and administrative overhead.
This reporting period reflects a pure consumption phase where development milestones dictate the velocity of cash burn.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
What are the financial strengths and risks for Scholar Rock Holding (SRRK)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The balance sheet is structured around cash reserves, which must fund all clinical programs until a drug reaches the market or a new financing event occurs. Current liquidity holds a comfortable margin over the near-term cash burn rate, providing a temporary runway for continued research.
The primary risk lies in trial failure or regulatory delay, which would force the company to raise fresh capital under distressed conditions before securing a commercial revenue stream.
What should you watch next at Scholar Rock Holding (SRRK)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $4.51M · EPS -3.20 · 12 analysts.
Research dated 2026-09-13.
Market watchers are closely tracking upcoming financial disclosures for updates on the clinical timeline of the lead spinal muscular atrophy asset and the early-stage solid tumor program. Cash runway projections remain the most critical metric in upcoming filings, as any acceleration in research spending shortens the window before the company must secure additional funding.
Furthermore, observers monitor the ongoing partnership with Gilead Sciences for any milestone progress in their joint fibrotic disease pipeline.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for SRRK.
Checked against the records this page reads, on the dates shown above.
How does Scholar Rock Holding compare with its peers?
Short answer
Scholar Rock Holding's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Unlike commercial-stage biotechnology firms that balance research spending with drug sales, Scholar Rock is defined entirely by its unapproved pipeline. Its specific focus on inhibiting the activation of latent myostatin distinguishes its scientific approach from peers utilizing standard gene therapies or broad immunosuppressants.
The heavy concentration of institutional ownership suggests the market treats the stock as a binary bet on its unique protein growth factor signaling platform rather than a traditional fundamental investment.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.89 Nov 20, 2026 | $7.38B | 98 5-pillar Nov 18, 2026 | |
| $308.89 Nov 20, 2026 | $9.15B | 96 5-pillar Nov 18, 2026 | |
| $63.62 Nov 20, 2026 | $6.96B | 91 5-pillar Nov 18, 2026 | |
| $121.40 Nov 20, 2026 | $7.92B | 88 5-pillar Nov 18, 2026 | |
| $39.91 Nov 20, 2026 | $4.37B | 84 5-pillar Nov 18, 2026 | |
| $17.58 Nov 20, 2026 | $5.04B | 83 5-pillar Nov 18, 2026 | |
| $286.85 Nov 20, 2026 | $5.74B | 71 5-pillar Nov 18, 2026 | |
| $95.81 Nov 20, 2026 | $6.50B | 67 5-pillar Nov 18, 2026 | |
| $13.61 Nov 20, 2026 | $4.78B | 67 5-pillar Nov 18, 2026 | |
| $119.52 Nov 20, 2026 | $5.04B | 66 5-pillar Nov 18, 2026 | |
| $127.38 Nov 20, 2026 | $5.17B | 64 5-pillar Nov 18, 2026 | |
| $37.04 Nov 20, 2026 | $3.64B | 56 5-pillar Nov 18, 2026 | |
| Scholar Rock Holding (SRRK) — this page | $48.13 | $5.87B | 21 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $58.00 – $84.00
- Consensus target
- $71.30
- Median target
- $71.00
- Revenue estimate
- $4.51M
- EPS estimate
- $-3.20
Consensus record · Captured .
Measured against a quoted price of $48.13 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 26, 2026
- Transactions
- 35
- Identified insiders
- 9
- Purchases
- 6
- Sales
- 13
- Other transactions
- 16
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SRRK in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SRRK in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Scholar Rock Holding (SRRK)?
SRRK Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does the Gilead Sciences partnership affect the pipeline?
The strategic collaboration focuses on developing targeted inhibitors for fibrotic diseases. This partnership allows the company to expand its therapeutic reach beyond core muscular and oncology programs without bearing the entire research burden alone, a crucial benefit for a pre-revenue biopharmaceutical firm.
Why are net losses growing despite successful clinical trial conclusions?
Advancing a therapeutic candidate through late-stage development and preparing for potential commercialization requires aggressive spending on research and administration. Because the company generates no product sales, these escalating trial costs flow directly to the bottom line as widening losses.
What provides the capital runway for the apitegromab regulatory review process?
The company maintains a substantial reserve of cash and short-term investments that comfortably exceeds its annualized operating cash drain. This liquidity buffer is designed to fund operations through the immediate clinical milestones without requiring imminent equity dilution.
Are corporate insiders accumulating shares as the lead therapy nears potential approval?
Recent filings show a pattern of net selling among corporate officers. Distinct insiders have disposed of shares over the trailing period, opting for liquidity rather than accumulating more equity as the clinical pipeline advances.
What is the SRRK stock price today?
The last price recorded for Scholar Rock Holding Corporation (SRRK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SRRK price target?
The analyst consensus price target for Scholar Rock Holding Corporation (SRRK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 18 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold SRRK
Funds in our ETF coverage that list SRRK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 4.06% |